Polymer compositions and methods for their use

• US 20050178396A1
• Filed: 12/07/2004
• Published: 08/18/2005
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Takacs-Cox, Aniko, Hunter, William L., Toleikis, Philip M., Avelar, Rui, Gravett, David M., Loss, Troy A. E., Liggins, Richard T., Maiti, Arpita
• Application Number:
  US11/006,905
• Publication Number:
  US 20050178396A1
• Time in Patent Office: Days
• US Class Current: 128/898
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

Claims

1-8063. -8063. (canceled)

8064. A method for reducing cartilage loss following a meniscal tear in a patient in need thereof, comprising delivering to the patient a) an anti-fibrotic agent or b) a composition comprising i) an anti-fibrotic agent and ii) a polymer and/or a compound that forms a polymer in situ.

8066. The method of claim 8064 or claim 8065 wherein the agent or composition is delivered intra-articularly.

8067. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits cell regeneration.

8068. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits angiogenesis.

8069. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits fibroblast migration.

8070. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits fibroblast proliferation.

8071. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits deposition of extracellular matrix.

8072. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits tissue remodeling.

8075. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a chemokine receptor antagonist.

8076. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a cell cycle inhibitor.

8077. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a taxane.

8078. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is an anti-microtubule agent.

8079. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is paclitaxel.

8080. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is not paclitaxel.

8081. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is an analogue or derivative of paclitaxel.

8082. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a vinca alkaloid.

8083. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is camptothecin or an analogue or derivative thereof.

8084. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a podophyllotoxin.

8085. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is etoposide or an analogue or derivative thereof.

8086. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is an anthracycline.

8087. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is doxorubicin or an analogue or derivative thereof.

8088. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is mitoxantrone or an analogue or derivative thereof.

8089. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a platinum compound.

8090. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a nitrosourea.

8091. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a nitroimidazole.

8092. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a folic acid antagonist.

8093. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a cytidine analogue.

8094. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a pyrimidine analogue.

8095. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a fluoropyrimidine analogue.

8096. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a purine analogue.

8097. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a nitrogen mustard or an analogue or derivative thereof.

8098. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a hydroxyurea.

8099. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a mytomicin or an analogue or derivative thereof.

8104. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a DNA alkylating agent.

8105. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is an anti-microtubule agent.

8106. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a topoisomerase inhibitor.

8107. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a DNA cleaving agent.

8108. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is an antimetabolite.

8109. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits adenosine deaminase.

8110. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits purine ring synthesis.

8111. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent is a nucleotide interconversion inhibitor.

8112. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent inhibits dihydrofolate reduction.

8113. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent blocks thymidine monophosphate.

8114. The method of claim 8064 or claim 8065, wherein the anti-fibrotic agent causes DNA damage.

8065. A method for preventing cartilage loss following a meniscal ligament tear in a patient in need thereof, comprising delivering to the patient a) an anti-fibrotic agent or b) a composition comprising i) an anti-fibrotic agent and ii) a polymer and/or a compound that forms a polymer in situ.

8073. (canceled)

8074. (canceled)

8100-8103. -8103. (canceled)

8115-8822. -8822. (canceled)